SEC Contract Filing

Filing Date: 2019-10-29

Document Content:
<DOCUMENT>
<TYPE>EX-10.2.2
<SEQUENCE>6
<FILENAME>incy-20190930ex10225e24a.htm
<DESCRIPTION>EX-10.2.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge 9.4.0.81-->
<!--Created on: 10/29/2019 6:32:00 PM-->
<html>
	<head>
 <title>
 incy_Ex_10_2_2
 </title>
	</head>
	<body><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

 <p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">

 <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit&nbsp;10.2.2</font>

 </p>

 <p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">

 <font style="display:inline;font-weight:bold;font-size:11pt;text-decoration:underline;">CONFIDENTIAL TREATMENT MATERIAL</font>

 </p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">EXTENSION OF CONFIDENTIAL TREATMENT REQUESTED:&nbsp; Certain identified information, marked by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.&nbsp; An extension of confidential treatment for such information has been requested.&nbsp; An unredacted version of this document has been filed separately with the Securities and Exchange Commission (the &#x201C;Commission&#x201D;).</font>
 </p>
 <p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">THIRD AMENDMENT</font>
 </p>
 <p style="margin:0pt 0pt 10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This Third Amendment (&#x201C;Third Amendment&#x201D;) is entered into effective March 31, 2016 (the &#x201C;Third Amendment Effective Date&#x201D;) by and between Incyte Corporation (&#x201C;Incyte&#x201D;), a Delaware corporation having an office at 1801 Augustine Cut-off, Wilmington, DE 19803, and Eli Lilly and Company (&#x201C;Lilly&#x201D;), an Indiana corporation having an office at Lilly Corporate Center, Indianapolis, IN 46285.</font>
 </p>
 <p style="margin:0pt 0pt 10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">RECITALS</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">A.&nbsp;&nbsp;&nbsp;Incyte and Lilly are parties to (i) a License, Development and Commercialization Agreement, effective December 18, 2009, (ii) an Amendment, effective June 22, 2010, and (iii) a Second Amendment, effective August 1, 2011, pursuant to which Incyte has granted Lilly an exclusive License to develop and commercialize Licensed Compounds and Licensed Products in the Field (such Agreement, as so amended, the &#x201C;Agreement&#x201D;).</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">B.&nbsp;&nbsp;&nbsp;The Parties now desire to further amend the Agreement by excluding Ruxolitinib (as defined below) for use in the Graft-Versus-Host Disease Field (as defined below) from the prohibition in Section 2.6 against Incyte Developing or Commercializing JAK2 Inhibitor Compounds in the Field in exchange for certain payments by Incyte and the waiver by Incyte of its Co-Promotion Option.</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">C.&nbsp;&nbsp;&nbsp;Unless otherwise defined herein, all capitalized terms appearing in this Third Amendment shall have the meaning set forth in the Agreement.</font>
 </p>
 <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font>
 </p>
 <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-size:11pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
 <font style="display:inline;font-family:Times N